GLP1R and atherosclerosis: Recent studies have demonstrated that the endothelium does not possess the GLP-1 receptor [35, 36], suggesting that the beneficial effects of GLP-1 receptor agonist therapy on cardiovascular events and atherosclerosis may be explained by indirect mechanisms rather than direct action on endothelial cells.